ArticleMalariaWorld journal2012
Formulation of quinine suppository for initiation of early treatment of malaria - a preliminary study.
Article in MalariaWorld journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the management of malaria, there is the need for early initiation of treatment. An antimalarial drug for home use must be easy to administer, safe, effective and affordable. Parenteral quinine is the gold standard for treatment of severe malaria. A rectal formulation of quinine will therefore serve the purpose of early initiation of care in patients that lack easy access to medical centers. The main objective of this preliminary work was to develop a quinine suppository with adequate release properties that also meets the dual conditions of affordability and ease of administration. Materials and Methods: Cocoa butter and Fattibase™ were used in the preparation of suppositories containing 200 mg quinine bisulphate. The release profiles of formulations with varying concentrations of polysorbate 80 (0 - 5%) were evaluated by in vitro dissolution in pH 8 buffer medium. Results: The addition of polysorbate 80 improved the release of quinine significantly at 2 and 5%. Cocoa butter suppository with 1% polysorbate 80 released 73.6 mg quinine bisulphate in 1 hr while release from suppositories with 2% and 5% surfactant was higher. Fattibase™ suppositories had better release profiles than cocoa butter formulations. The formulation with 5% polysorbate 80 released 170 mg quinine in 1 hr. Formulations with the two bases released quinine in adequate quantities for the management of malaria. Conclusions: The particle size of quinine is an important factor affecting the physical appearance and drug release from the suppository. The Fattibase™ suppositories were more stable but cost five times the price of the cocoa butter formulations. The cocoa butter formulations, however, still released quinine in sufficient quantities for the management of malaria. Cocoa butter formulations will be more affordable in resource-limited malaria-endemic regions of the world.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.